Thus, targeting the ARK1C3/AR/AR-V7 axis with PTUBP and enzalutamide can overcome drug resistance to AR signaling inhibitors in CRPC using a combination of patient-derived models (CRC, organoids, and PDX) and traditional cell lines and their corresponding xenografts [71]. Here, AR is linked to colorectal carcinoma.